FDA Clearance Tracker · DEN180057
IB-Stim
Last checked: Nov 20, 2026Latest source record: Jun 7, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Jun 7, 2019
De Novo granted
Time to decision
225 days
Received Oct 25, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN180057
- Device name
- IB-Stim
- Applicant location
- Versailles, IN
- Received
- Oct 25, 2018
- Decided
- Jun 7, 2019
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device type
- Non-Implanted Nerve Stimulator For Pain Associated With Irritable Bowel Syndrome (Ibs) (QHH)
- Device class
- Class II
- Regulation
- 21 CFR 876.5340
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for DEN180057
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Innovative Health Solutions (Ihs), Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- NSS-2 SystemNew device typeDe Novo
DEN170018 · Decided Nov 15, 2017 · 243 days after receipt
Device type: Percutaneous Nerve Stimulator For Opioid Withdrawal (PZR) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.